

-1G. 1A







FIG. 2










F/G. 5



Proteinuria (mg/day) in diabetic rats (early phase)

MACALLA	logo.	40	*26	35	45	52
Weeks	Weeks Dasai	10		8	2	
1304	20.23±0.99	27.95±1.76	61.47±2.80**	76.58±11.78**	126.04±13.46**	.20.23±0.99   27.95±1.76   61.47±2.80**   76.58±11.78**   126.04±13.46**   174.41±12.15**
1011	19.78±1.33	27.36±2.10	62.55±3.82**	1D11 : 19.78±1.33 27.36±2.10 62.55±3.82** 67.20±4.61** 68.88±6.82*	68.88±6.82°	81.21±15.30°°
Enalapril	-18.80±1.32	28.88±1.53	60.67±3.70**	Enalapril -18:80±1.32 28.88±1.53 60.67±3.70** 57.48±3.56** 63.61±6.71**	1	69.25±4.80°°
Control	"19.93±1.78	21.90±0.88	Control :19.93±1.78 21.90±0.88 29.63±1.59 39.06±2.42	39.06±2.42	1	55.31±2.64

Before treatment.

Values are expressed as mean±SE. \*\*p<0.01 vs control; °p<0.05, °p<0.01 vs. 13C4. Therapies were given from 27:to 52 weeks after disease induction by streptozotocin (60 mg/kg i.v.).

Eig 7

Proteinuria (mg/day) in diabetic rats (late phase)

Weeks	Basal	: 18	:27	. 36	45	*25	. 61
13C4	19.63±1.05	27.86±2.15	3±1.05 [27:86±2.15   59.14±2.23**   79:04±7.11**   115.55±9.91**	79:04±7:11**		160.87±12.22**   181.93±18.95**	181.93±18.95**
1011	21.87±2.10	28.82±4.23	21:87±2.10   28:82±4:23   57.07±6.75**   75:21±8:30**   112.58±7.72**	75:21±8:30**	l i	159.14±5.45**	149.22±20.05*
Enalapril	17.12±0.65	728,49±1.58	2±0.65 [28,49±1.58   57.01±4.80**   71.29±8.96**   110.78±8.26**	71:29±8.96**	110.78±8.26**	156.94±12.93** 159.73±20.96*	159.73±20.96*
. 1D11+enalaptil - 19.52	.19.52±0.72	24.78±0.90	59.07±3.93**	77:30±1.90**	111.91±14.17**	2±0.72 :24.78±0.90   59.07±3.93**   77:30±1.90**   111.91±14.17**   155.20±10.17**   99.61±13.76°	99.61±13.76°
Control	20.57±2.03	7±2.03   21,70±1.05   29.85±1.93		39.03±2.96	50,44±3.62	57.98±6.42	62.84±13.34

\* Before treatment.

Values are expressed as mean±SE. \*\*p<0.01 vs control, °p<0.05 vs 13C4. Therapies were given from 52 to 61 weeks after disease induction by streptozotocin (60 mg/kg i.v.).